论文部分内容阅读
欧委会于2007-11-26批准WyethPharmaceuticals,Inc生产的temsirolimus(Torisel)为晚期肾细胞癌的一线治疗药物,用于那些存在至少3个预知风险因素的患者。这些风险因素包括:初次确诊后已过去不到一年的时间;KPS(Karnofsky performance status)评分为60或70;
The European Commission approved temsirolimus (Torisel) from Wyeth Pharmaceuticals, Inc. as a first-line treatment for advanced renal cell carcinoma on November 26, 2007, for patients with at least 3 predisposing risk factors. These risk factors include: less than a year has passed since initial diagnosis; KPS score of 60 or 70;